On this page
What should a safety pharmacology study report explain?
Explain the physiological function assessed, the test system, treatment and measurement timing, actual results, exposure context and limitations. Distinguish the study’s findings from the program-level safety judgment. Where functional endpoints are embedded in another study, identify that evidence rather than inventing a separate report.
Before you begin
Writing and reviewing available safety-pharmacology evidence. This page does not prescribe a core battery or a QT testing strategy for an unspecified product.
What you will prepare: A functional-safety report with reproducible endpoint context and an explicit disposition of signals and missing evidence.
Name the physiological question and evidence location
Identify the organ-system question, the measured endpoints and the role of this study in the development program. S7A distinguishes a core assessment of central nervous, cardiovascular and respiratory function from follow-up and supplemental work. Whether a separate study is appropriate depends on context; relevant endpoints can sometimes be incorporated into other studies.
When evidence is embedded in a toxicology report, point readers to the report and the specific functional results. Do not create a fictional standalone report to populate 4.2.1.3. Record the study's actual GLP status and the explanation of any relevant limitations; copying a generic “GLP compliant” footer is not evidence of compliance.
Make endpoint timing and exposure reconstructable
As an editorial working aid, build a timeline of administration, functional measurements, sample collection and notable observations. Collect the protocol, instrument or assay method, baseline handling, control results, concentration information, exclusions and analysis plan. Distinguish scheduled measurements from measurements actually obtained.
For cardiovascular work, identify the endpoints the experiment truly measured instead of using “cardiac safety” as a catch-all. For respiratory work, explain the measured function and recording conditions. For central nervous system observations, retain the assessment method and timepoints; a general statement of normal behavior cannot replace the recorded observations.
Describe confounders that affect interpretation, such as missing measurement intervals, handling effects or technically unusable recordings. Have the study scientist assess their impact. The author should not retrospectively redefine an endpoint solely to make an inconvenient result disappear.
Separate a signal from the program-level decision
Present the direction, timing and magnitude of observed effects, with the relevant controls and uncertainty. Explain which exposure evidence belongs to those measurements and where it is reported. A dose with no observed effect in one endpoint is not proof that every safety concern has been excluded.
The discussion should distinguish the study's conclusion from a separate clinical-risk interpretation or decision about follow-up. If follow-up occurred, link the actual evidence; if it is planned or unresolved, state that status. Check current product-specific guidance before treating an older general recommendation as the complete development strategy. This page deliberately does not specify contemporary S7B/QT assay acceptance thresholds.
Check a missing peak-effect interval
Fictional example: a telemetry report states that no treatment-related change occurred, but the recording was unusable during an interval expected to overlap high exposure. The reviewer should identify the lost interval, inspect the exposure rationale and request an impact assessment from the study lead.
The corrected report should state what the interpretable observations support and what they cannot exclude. The answer is neither an automatic negative finding nor an automatic requirement to repeat the experiment. The scientific and regulatory owners determine whether other evidence resolves the gap.
Review the overlap between measurements and exposure
Use a working observation map to make the report's conclusion testable. Record actual timing and data quality rather than only the intended schedule.
| Timeline element | Source record | Interpretation question |
|---|---|---|
| Treatment | Actual administration record | Was treatment delivered as described? |
| Functional measurement | Endpoint output with time and quality disposition | Which physiological interval is interpretable? |
| Exposure evidence | Concentration record or referenced kinetic assessment | How does it relate to the measured interval? |
| Signal | Individual and group results with controls | Is the effect consistent across relevant observations? |
| Follow-up | Actual additional measurements or assessment | What uncertainty did the follow-up resolve? |
Separate a missing observation from an observation showing no effect. Both may leave a blank-looking cell in a summary spreadsheet, but they carry very different meanings. Use explicit entries such as “not collected,” “technically unusable,” or the observed result, with the scientist's impact assessment where needed.
Review exercise: measurements before and after an interruption are interpretable, but the critical interval is unavailable. The report can describe the available observations. Whether they adequately address the study objective depends on the timing, exposure and other evidence; a writer should not interpolate an unobserved physiological result. Preserve that distinction in the pharmacology summary.
For findings embedded in general toxicology, record the exact endpoint location and the design features needed to interpret it. An organ name in a toxicity table is not sufficient evidence that a particular functional assessment was performed.
Your preparation checklist
0/4 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Must every safety pharmacology endpoint have a standalone report?
No. S7A recognizes that some endpoints can be incorporated into other studies. Identify the actual design, measurements and limitations and cross-reference the controlled report. Whether that evidence adequately answers the safety question requires a scientific assessment of the study context.
Does a normal toxicity study establish normal cardiovascular function?
Not automatically. Conventional toxicity observations may not detect functional effects that a safety pharmacology assessment is designed to evaluate. Specify the cardiovascular endpoints actually measured, their timing and interpretability before drawing a conclusion about the function in question.
Can this guide establish current QT or proarrhythmia acceptance criteria?
No. This report-writing guide uses S7A for general safety pharmacology principles and does not provide contemporary QT or proarrhythmia criteria. Determine the applicable current guidance and product context separately, then describe the actual methods and justified interpretation in the report.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Technical specification
FDA eCTD v4.0 headings and hierarchy ↗Version 2.2, February 2025; Module 4, printed pages 6–10. Technical placement and allowable document types, not a required-study list. Checked September 22, 2026.
Guidance
ICH S7A: safety pharmacology studies ↗Step 4, November 8, 2000; sections 2.7–2.11 and note 2. The historical note anticipating S7B is not current QT guidance. Checked September 22, 2026.
FDA resource
FDA streamlined nonclinical studies and NAMs ↗Live CDER resource checked September 22, 2026. Product-specific recommendations and links include draft guidance; inspect the applicable linked document before making a study-plan decision.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 4.2.1.3. A heading identifies placement, not mandatory applicability.